Independent Research GmbH announced Fresenius (ETR:FRE), bumping up its stock price target to 77.00EUR today
- Updated: September 18, 2016
Stating a possible upside of 0.17%, Independent Research GmbH raised the estimated target of Fresenius (ETR:FRE) to 77EUR.
Previously on 8/03/2016, Independent Research GmbH released a statement on Fresenius(ETR:FRE) bumped the target price from 0.00EUR to 77.00EUR. At the time, this indicated a possible upside of 0.17%.
Displaying a price of 65.99EUR, Fresenius (ETR:FRE) traded 0.00% even on the day. With the last close up 0.00% from the two hundred day moving average, compared with the S&P 500 Index which has fallen -0.01% over the same time period. Fresenius has recorded a 50-day average of 0.00EUR and two hundred day average of 0.00EUR. Trade volume was held steady, with 0 shares of FRE changing hands on par with the typical 0 shares.
With a market capitalization of 0.0 EUR, Fresenius has a P/E of 0 with a one-year low of 0.00EUR and a 52 week high of 0.00EUR.
General Company Details For Fresenius (ETR:FRE)
Fresenius SE & Co KGaA is a health care company. It operates in the healthcare sector and offers products and services for dialysis, hospitals and outpatient medical care. It focuses on the hospital operations and offers engineering and services for hospitals and other health care facilities. The Company’s operating segments include Fresenius Medical Care; Fresenius Kabi; Fresenius Helios and Fresenius Vamed. The Fresenius Medical Care segment provides dialysis care and dialysis products for patients with chronic kidney failure. The Fresenius Kabi segment is engaged in provision of intravenously administered drugs (IV drugs), infusion therapies, and clinical nutrition and outpatient care. The Fresenius Helios segment is a private hospital operator and operates 72 clinics. The Fresenius Vamed segment provides engineering and services for hospitals and other health care facilities internationally.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.